We are a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease (“IBS”), chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of HSV-1 is triggered by some form of environmental and/or health stressor.
Our lead development candidate (“IMC-1”), is a novel proprietary fixed-dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.
|Address||44 Milton Avenue Alpharetta, GA 30009|
|Phone Number||(866) 620-8655|
|View Prospectus:||Virios Therapeutics|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-3.6 mil (last 12 months)|
|Price range||$9.00 - $11.00|
|Est. $ Volume||$30.0 mil|
|Manager / Joint Managers||ThinkEquity (a division of Fordham Financial Management)|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|